{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:22:58Z","timestamp":1761895378201},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2011,11,14]],"date-time":"2011-11-14T00:00:00Z","timestamp":1321228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,11,14]],"date-time":"2011-11-14T00:00:00Z","timestamp":1321228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1038\/bmt.2011.218","type":"journal-article","created":{"date-parts":[[2011,11,14]],"date-time":"2011-11-14T11:57:58Z","timestamp":1321271878000},"page":"1082-1086","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance"],"prefix":"10.1038","volume":"47","author":[{"given":"T","family":"Ahmadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Frey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A W","family":"Loren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S C","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S J","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S D","family":"Nasta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,11,14]]},"reference":[{"key":"BFbmt2011218_CR1","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","volume":"16","author":"JO Armitage","year":"1998","unstructured":"Armitage JO, Weisenburger DD . New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780\u20132795.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011218_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","volume":"6","author":"E Zucca","year":"1995","unstructured":"Zucca E, Roggero E, Pinotti G, Pedrinis E, Cappella C, Venco A et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6: 257\u2013262.","journal-title":"Ann Oncol"},{"key":"BFbmt2011218_CR3","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","volume":"20","author":"OM Howard","year":"2002","unstructured":"Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288\u20131294.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011218_CR4","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984\u20131992.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011218_CR5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","volume":"102","author":"AM Gianni","year":"2003","unstructured":"Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003; 102: 749\u2013755.","journal-title":"Blood"},{"key":"BFbmt2011218_CR6","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1002\/cncr.11838","volume":"98","author":"IF Khouri","year":"2003","unstructured":"Khouri IF, Saliba RM, Okoroji GJ, Acholonu SA, Champlin RE . Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003; 98: 2630\u20132635.","journal-title":"Cancer"},{"key":"BFbmt2011218_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","volume":"120","author":"E Vandenberghe","year":"2003","unstructured":"Vandenberghe E, Ruiz de Elvira C, Loberiza FR, Conde E, Lopez-Guillermo A, Gisselbrecht C et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003; 120: 793\u2013800.","journal-title":"Br J Haematol"},{"key":"BFbmt2011218_CR8","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677\u20132684.","journal-title":"Blood"},{"key":"BFbmt2011218_CR9","first-page":"1275","volume":"89","author":"F Lefrere","year":"2004","unstructured":"Lefrere F, Delmer A, Levy V, Delarue R, Varet B, Hermine O . Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 2004; 89: 1275\u20131276.","journal-title":"Haematologica"},{"key":"BFbmt2011218_CR10","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"JE Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013\u20137023.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011218_CR11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","volume":"150","author":"JE Romaguera","year":"2010","unstructured":"Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150: 200\u2013208.","journal-title":"Br J Haematol"},{"key":"BFbmt2011218_CR12","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687\u20132693.","journal-title":"Blood"},{"key":"BFbmt2011218_CR13","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","volume":"27","author":"H Hochster","year":"2009","unstructured":"Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009; 27: 1607\u20131614.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011218_CR14","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH van Oers","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295\u20133301.","journal-title":"Blood"},{"key":"BFbmt2011218_CR15","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","volume":"17","author":"BS Kahl","year":"2006","unstructured":"Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006; 17: 1418\u20131423.","journal-title":"Ann Oncol"},{"key":"BFbmt2011218_CR16","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003\u20134008.","journal-title":"Blood"},{"key":"BFbmt2011218_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","volume":"27","author":"A Herrmann","year":"2009","unstructured":"Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27: 511\u2013518.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011218_CR18","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","volume":"20","author":"JD Hainsworth","year":"2002","unstructured":"Hainsworth JD, Litchy S, Burris III HA, Scullin Jr DC, Corso SW, Yardley DA et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261\u20134267.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011218_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579\u2013586.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011218_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","volume":"23","author":"M GhieDmini","year":"2005","unstructured":"GhieDmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23: 705\u2013711.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2011218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2011218","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2011218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T18:03:34Z","timestamp":1713117814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2011218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,14]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["BFbmt2011218"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2011.218","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,14]]},"assertion":[{"value":"25 May 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}